Study of pheochromocytoma and paraganglioma in patients
Part of Cancer clinical trials.
This study looks at people who have been newly diagnosed with pheochromocytoma/paraganglioma (PPGL), those with a past history of PPGL, or those with genetic risk for it. It may help doctors better evaluate and understand PPGL using specific tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 5 or older and have PPGL or be at genetic risk for PPGL
- Either be newly diagnosed, have had PPGL before, or carry a known PPGL-causing genetic mutation
- Understand the study and sign the informed consent form (and get parent/guardian consent for children)
- Be able to participate despite any learning/cognitive limits that prevent understanding or consent
- If you are pregnant, you can join but you would not have certain scans or tests (including PET, MIBG, clonidine testing, or contrast CT)
- Be able to safely do MRI (no metal implants that could be unsafe, and you should not have severe fear of enclosed spaces)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps doctors better understand and diagnose pheochromocytoma and paraganglioma—rare tumors that release stress hormones and cause high blood pressure and other symptoms. Researchers will study your medical history, blood and urine tests, imaging scans, and genetic information to improve how these conditions are found and understood.
This study looks at how the immune system responds to rare adrenal or nerve-related tumors (pheochromocytoma and paraganglioma). Researchers want to understand the tumor's environment, which may help improve future treatments.
This study looks at past patient data to find patterns that might predict whether a pheochromocytoma or paraganglioma (rare tumors of the adrenal glands or nerve tissue) will spread. It aims to create a tool to help doctors estimate risk and plan treatment.
This trial tests a drug called belzutifan to see how it affects hormone levels in people with rare adrenal tumors (pheochromocytoma or paraganglioma). It may help control symptoms caused by excess hormones.
This study looks at genetic (DNA) changes in people with pheochromocytoma or paraganglioma and related conditions. It may help clarify why these conditions happen and how they run in families.
This study uses a special PET scan (called 18F-mFBG) to get clearer pictures of pheochromocytoma, a rare adrenal tumor. It may help doctors better understand your tumor and guide treatment.
Hear when a new Pheochromocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.